Literature DB >> 33136179

Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters.

Lata Singh1,2,3, Mithalesh Kumar Singh1, Maria Cristina Kenney2, Martine J Jager4, Moshahid Alam Rizvi3, Rachna Meel5, Neiwete Lomi5, Sameer Bakhshi6, Seema Sen1, Seema Kashyap7.   

Abstract

BACKGROUND: To understand how to improve the effect of immune checkpoint inhibitors in uveal melanoma (UM), we need a better understanding of the expression of PD-1 and PD-L1, their relation with the presence of tumor-infiltrating lymphocytes (TILs), and their prognostic relevance in UM patients.
MATERIALS AND METHODS: Expression of PD-1 and PD-L1 was assessed in 71 UM tissue samples by immunohistochemistry and quantitative real-time PCR (qRT-PCR), and further validated by western blotting. The effect of interferon gamma (IFN-γ) on PD-1/PD-L1 expression was determined on four UM cell lines.
RESULTS: Immunoreactivity of PD-1 was found in 30/71 cases and of PD-L1 in 44/71 UM samples. Tumor-infiltrating lymphocytes were found in 46% of UM tissues. PD-1 was expressed on TILs while tumor cells expressed PD-L1. UM with and without TILs showed expression of PD-1 in 69% and 18% cases, respectively (p = 0.001). Similarly, PD-L1 was found in 75% of UM with TILs and in 50% of cases without TILs, respectively (p = 0.03). DFS rate were lower in patients with TILs with expression of PD-1 and PD-L1, but the rate of DFS was higher with expression of PD-L1 in patients without TILs. After treatment of UM cell lines with IFN-γ, PD-1 expression was induced in all UM cell lines whereas PD-L1 expression was found at a lower level in untreated cells, while expression also increased following treatment with IFN-γ.
CONCLUSION: Our study suggests that increased infiltration with TILs promotes the aggressive behavior and suppresses the immune response of UM cells, thereby inhibiting immunotherapy.

Entities:  

Keywords:  Immunotherapy; Interferon gamma; Tumor-infiltrating lymphocytes; Uveal melanoma

Mesh:

Substances:

Year:  2020        PMID: 33136179     DOI: 10.1007/s00262-020-02773-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  36 in total

Review 1.  Uveal Melanoma UK National Guidelines.

Authors:  P Nathan; V Cohen; S Coupland; K Curtis; B Damato; J Evans; S Fenwick; L Kirkpatrick; O Li; E Marshall; K McGuirk; C Ottensmeier; N Pearce; S Salvi; B Stedman; P Szlosarek; N Turnbull
Journal:  Eur J Cancer       Date:  2015-08-13       Impact factor: 9.162

Review 2.  Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.

Authors:  Kimberly M Komatsubara; Richard D Carvajal
Journal:  Curr Oncol Rep       Date:  2017-07       Impact factor: 5.075

Review 3.  Tumors as organs: complex tissues that interface with the entire organism.

Authors:  Mikala Egeblad; Elizabeth S Nakasone; Zena Werb
Journal:  Dev Cell       Date:  2010-06-15       Impact factor: 12.270

4.  Frequent mutation of BAP1 in metastasizing uveal melanomas.

Authors:  J William Harbour; Michael D Onken; Elisha D O Roberson; Shenghui Duan; Li Cao; Lori A Worley; M Laurin Council; Katie A Matatall; Cynthia Helms; Anne M Bowcock
Journal:  Science       Date:  2010-11-04       Impact factor: 47.728

Review 5.  Uveal melanoma: epidemiologic aspects.

Authors:  Arun D Singh; Louise Bergman; Stefan Seregard
Journal:  Ophthalmol Clin North Am       Date:  2005-03

6.  Local Recurrence After Primary Proton Beam Therapy in Uveal Melanoma: Risk Factors, Retreatment Approaches, and Outcome.

Authors:  Ira Seibel; Dino Cordini; Matus Rehak; Annette Hager; Aline I Riechardt; Alexander Böker; Jens Heufelder; Andreas Weber; Johannes Gollrad; Angela Besserer; Antonia M Joussen
Journal:  Am J Ophthalmol       Date:  2015-06-29       Impact factor: 5.258

7.  Management of uveal melanoma: a consensus-based provincial clinical practice guideline.

Authors:  E Weis; T G Salopek; J G McKinnon; M P Larocque; C Temple-Oberle; T Cheng; J McWhae; R Sloboda; M Shea-Budgell
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

Review 8.  Locoregional management of hepatic metastasis from primary uveal melanoma.

Authors:  Takami Sato
Journal:  Semin Oncol       Date:  2010-04       Impact factor: 4.929

Review 9.  Uveal melanoma.

Authors:  Seema Kashyap; Rachna Meel; Lata Singh; Mithalesh Singh
Journal:  Semin Diagn Pathol       Date:  2016-03-10       Impact factor: 3.464

Review 10.  Current and emerging treatment options for uveal melanoma.

Authors:  Patricia Rusa Pereira; Alexandre Nakao Odashiro; Li-Anne Lim; Cristina Miyamoto; Paula L Blanco; Macanori Odashiro; Shawn Maloney; Dominique F De Souza; Miguel N Burnier
Journal:  Clin Ophthalmol       Date:  2013-08-22
View more
  5 in total

Review 1.  Recent Advances and Challenges in Uveal Melanoma Immunotherapy.

Authors:  Yihang Fu; Wei Xiao; Yuxiang Mao
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

Review 2.  Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction.

Authors:  József Tímár; Andrea Ladányi
Journal:  Int J Mol Sci       Date:  2022-05-11       Impact factor: 6.208

3.  Monosomy-3 Alters the Expression Profile of the Glucose Transporters GLUT1-3 in Uveal Melanoma.

Authors:  Tjorge Maaßen; Siranush Vardanyan; Anton Brosig; Hartmut Merz; Mahdy Ranjbar; Vinodh Kakkassery; Salvatore Grisanti; Aysegül Tura
Journal:  Int J Mol Sci       Date:  2020-12-08       Impact factor: 5.923

Review 4.  Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions.

Authors:  Nuno Jorge Lamas; Arnaud Martel; Sacha Nahon-Estève; Samantha Goffinet; Adam Macocco; Corine Bertolotto; Sandra Lassalle; Paul Hofman
Journal:  Cancers (Basel)       Date:  2021-12-25       Impact factor: 6.639

5.  Case Report: Differential Genomics and Evolution of a Meningeal Melanoma Treated With Ipilimumab and Nivolumab.

Authors:  Remberto Burgos; Andrés F Cardona; Nicolas Santoyo; Alejandro Ruiz-Patiño; Juanita Cure-Casilimas; Leonardo Rojas; Luisa Ricaurte; Álvaro Muñoz; Juan Esteban Garcia-Robledo; Camila Ordoñez; Carolina Sotelo; July Rodríguez; Zyanya Lucia Zatarain-Barrón; Diego Pineda; Oscar Arrieta
Journal:  Front Oncol       Date:  2022-01-05       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.